Blair William & Co. IL Has $10.65 Million Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Blair William & Co. IL lifted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.0% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,855 shares of the company’s stock after purchasing an additional 1,004 shares during the period. Blair William & Co. IL owned 0.08% of Medpace worth $10,648,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Rise Advisors LLC bought a new position in Medpace during the first quarter worth about $27,000. Mather Group LLC. bought a new position in Medpace during the 1st quarter worth approximately $28,000. Fidelis Capital Partners LLC bought a new position in Medpace during the 1st quarter worth approximately $31,000. J.Safra Asset Management Corp grew its holdings in Medpace by 87.0% during the first quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock valued at $41,000 after purchasing an additional 47 shares during the period. Finally, DT Investment Partners LLC bought a new stake in Medpace in the second quarter valued at approximately $41,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Price Performance

Medpace stock opened at $369.18 on Friday. The company has a market cap of $11.44 billion, a price-to-earnings ratio of 37.63, a P/E/G ratio of 1.74 and a beta of 1.36. The firm has a 50-day moving average of $379.70 and a 200-day moving average of $392.28. Medpace Holdings, Inc. has a one year low of $227.21 and a one year high of $459.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, July 22nd. The company reported $2.75 EPS for the quarter, beating the consensus estimate of $2.54 by $0.21. The firm had revenue of $528.10 million during the quarter, compared to analysts’ expectations of $528.41 million. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The business’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.93 earnings per share. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 11.66 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on MEDP. Guggenheim reduced their price target on shares of Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a research report on Wednesday, July 24th. StockNews.com cut Medpace from a “buy” rating to a “hold” rating in a research note on Wednesday. TD Cowen lowered their price target on Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a report on Wednesday, July 24th. Robert W. Baird cut their price objective on Medpace from $469.00 to $430.00 and set an “outperform” rating on the stock in a report on Wednesday, July 24th. Finally, William Blair reissued an “outperform” rating on shares of Medpace in a research note on Wednesday, September 11th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $423.00.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.